REMISSION OF HYPERTENSION AT SIX MONTHS OF WHOLE BODY DIGITAL TWIN TECHNOLOGY

Abstract

Objective: Twin Precision Treatment (TPT) is a novel Whole-Body Digital Twin (WBDT) enabled precision nutrition which has been shown to reverse diabetes, that uses AI and the Internet of Things, to integrate multidimensional data, from non-invasive sensors, to give precision nutrition and health recommendations via the TPT app and by coaches Design and method: We conducted a pilot, prospective randomized trial (n = 20) to evaluate the impact of TPT on the blood pressure in hypertensives. Remission of hypertension was defined as conversion to normotensive status (SBP < 140mmHg and DBP < 90mmHg and no use of antihypertensive medication) at the follow-up visit. We did not enroll people with diabetes. Results: Mean age 49 years (±7.9, 95% CI 45 to 52). There were 12 males and 8 females. There was a significant change at 6 months in the SBP (mmHg) 140.2±15.8 reduced to 127.1±8.3, decrease by 13.1, p = 0.02, DBP 94.7±11.7 reduced to 86.8±6.4, decrease by 8, p = 0.014, body weight (kg) 83.4±17.2 reduced to 73±14.9, decrease by 10, p<0.001, BMI (kg/m 2) 30.9±4.8 reduced to 26.7±3.9, decrease by 4.2, p<0.001 and waist circumference (cm) 103.8±13 reduced to 94.1±11.4, decrease by 9.7, p<0.001. There were 12 patients who discontinued the medications that were needed to manage hypertension, with a remission rate of 60% (12/20). Conclusions: Our initial results of the pilot, prospective study demonstrate that TPT has the potential to induce remission of hypertension at six months. However, the continuity of this study in terms of a larger number of patients and longer duration will further provide insights into the consistency and the scalability of the novel TPT to achieve remission of hypertension.